 |
NIH NEWS RELEASE
For more information, go to www.nei.nih.gov/eyedata/.
B-roll with eye examinations is available by calling
301-496-5248. Simulations of visual impairments
and other images are available in downloadable,
camera-ready format on the NEI Website at www.nei.nih.gov/photo/
|
National Eye Institute
www.nei.nih.gov
Contact:
Michael Coogan
NEI Communication Office
Telephone: 301-496-5248
mjc@nei.nih.gov
Embargoed for Release by the Journal until Monday,
April 12, 2004 (4 PM ET)
Vision Loss from Eye Diseases Will Increase as Americans
Age
With the aging of the population, the number of Americans
with major eye diseases is increasing, and vision loss
is becoming a major public health problem. By the year
2020, the number of people who are blind or have low vision
is projected to increase substantially. These findings
appear in the April issue of Archives
of Ophthalmology.
Blindness or low vision affects 3.3 million Americans
age 40 and over, or one in 28, according to study authors.
This figure is projected to reach 5.5 million by the year
2020. The study reports that low vision and blindness increase
significantly with age, particularly in people over age
65. People 80 years of age and older currently make up
eight percent of the population, but account for 69 percent
of blindness. The study provides the most robust and up-to-date
estimates available of the burden of visual impairment.
It was sponsored by the National Eye Institute (NEI), part
of the Federal government's National Institutes of Health
(NIH).
"Blindness and low vision can lead to loss of independence
and reduced quality of life," said Elias A. Zerhouni, M.D.,
Director of the NIH. "As our population lives longer, eye
disease will be an ever greater concern. These data underscore
NIH's commitment to the support of vision research that
will prevent, delay, and possibly cure eye diseases."
The study identifies age-related macular degeneration
(AMD), glaucoma, cataract, and diabetic retinopathy as
the most common eye diseases in Americans age 40 and over.
The leading cause of blindness among white Americans is
AMD, accounting for 54 percent of all blindness. Among
African Americans, the leading causes of blindness are
cataract and glaucoma. Among Hispanics, glaucoma is the
most common cause of blindness. The study authors emphasize
the importance of annual comprehensive eye examinations
in preventing and/or delaying eye disease for those at
higher risk for blindness, such as those over age 65, people
with diabetes, or African Americans over age 40.
Study authors provide estimates of the number of Americans
with each disease. The authors say that due largely to
the aging of the population, the prevalence of low vision
and blindness will increase markedly by 2020.
Eye Disease Prevalence and Projections
(Number of Adults 40 Years and Older in the
U.S.)
| |
Current
Estimates
(in millions)
|
2020
Projections
(in millions)
|
Advanced Age-Related
Macular Degeneration
(With Associated Vision Loss) |
1.8* |
2.9 |
| Glaucoma |
2.2 |
3.3 |
| Diabetic Retinopathy |
4.1 |
7.2 |
| Cataract |
20.5 |
30.1 |
* Another 7.3 million people are at substantial
risk for vision loss from AMD |
There were other significant findings from the study:
- AMD is strongly associated with increasing age, particularly
after age 60. AMD rises dramatically in whites over age
80; more than one in 10 white Americans over age 80 has
vision loss from AMD.
- Glaucoma is almost three times as common in African
Americans as in whites.
- The prevalence of glaucoma rises rapidly in Hispanics
over age 65.
- Cataract is the leading cause of low vision among all
Americans, responsible for about 50 percent of all cases.
- One in every 12 people with diabetes age 40 and older
has vision-threatening diabetic retinopathy.
"These data will help identify areas where we should direct
our research efforts," said NEI Director Paul A. Sieving,
M.D., Ph.D. "Also, health professionals and state and local
agencies can use study data to prioritize public health
programs emphasizing the importance of early detection
and timely treatment. Developing blindness prevention strategies
could help address the potentially devastating impact of
the increased prevalence of eye diseases in the next few
decades."
Frederick Ferris III, M.D., director of clinical research
at the NEI, said that the estimates of low vision and blindness "are
the first to take full advantage of information derived
from several excellent eye disease studies reported since
1990. These data, collected from different populations,
allow us to identify the most common eye diseases and give
us good estimates of their relative magnitudes."
The study was conducted by the Eye Disease Prevalence
Research Group, a consortium of principal investigators
who have conducted population-based eye disease studies.
The Eye Disease Prevalence Research Group produced prevalence
estimates of blindness and low vision in people age 40
and over by analyzing standardized data from several high
quality studies.The derived prevalence rates were then
modeled to the U.S. population using 2000 census data,
and projected to 2020 based on 2020 US census estimates.
A
list of the eye disease studies of various populations
analyzed by the Eye Disease Prevalence Research Group,
and their respective authors, and data
tables are attached.
The National Eye Institute (NEI) conducts and supports
research that leads to sight-saving treatments and plays
a key role in reducing visual impairment and blindness.
The NEI is part of the National Institutes of Health
(NIH), an agency of the U.S. Department of Health and
Human Services.
###
These statements have not been reviewed by
the Food and Drug Administration, and individual results
may vary. Individuals shown are paid models and not necessarily
Rogisen users. Rogisen should be taken as part of a healthy
lifestyle and is not intended to treat or cure any disease.
For telephone orders, please call 1-800-965-3989
|
















 |
“I rely on my eyes for so much.
Working, driving, casting a reel, watching my family grow
up. I’m not ready to give up any of that. Life’s
too short to miss a thing. That’s why I take Rogisen.”
|